We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Pharmacokinetics Study on Pikamilone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00940186
Recruitment Status : Completed
First Posted : July 15, 2009
Last Update Posted : July 15, 2009
Sponsor:
Information provided by:
Chinese Academy of Sciences

Brief Summary:
Study on the phamacokinetics of Pikamilone in healthy Chinese subject and provide informations for further phase II study.

Condition or disease
Healthy

Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Clinical Pharmacokinetics Study on Pikamilone
Study Start Date : March 2009
Study Completion Date : April 2009

Group/Cohort
pikamilone
dosage
low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
tablet



Biospecimen Retention:   Samples Without DNA
plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
15 male subjects and 15 female subjects were enrolled in this study. They were divided into three groups by random and each group contained 5 male and 5 female subjects.
Criteria

Inclusion Criteria:

  • nonsmokers and in good health
  • weight: BMI: 19-24
  • written informed consent was finished.

Exclusion Criteria:

  • disease
  • taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00940186


Locations
China, Liaoning
the second hospital to liaoning university of TCM
Shenyang, Liaoning, China, 110034
Sponsors and Collaborators
Chinese Academy of Sciences
Investigators
Study Chair: D F Zhong, PH.D Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Responsible Party: center for drug metabolism and pharmacokinetics, shanghai institute of materia medica
ClinicalTrials.gov Identifier: NCT00940186     History of Changes
Other Study ID Numbers: SIMM-DMPK-080901
First Posted: July 15, 2009    Key Record Dates
Last Update Posted: July 15, 2009
Last Verified: July 2009